These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
196 related articles for article (PubMed ID: 32916316)
41. Individualized drug therapy. Daly AK Curr Opin Drug Discov Devel; 2007 Jan; 10(1):29-36. PubMed ID: 17265738 [TBL] [Abstract][Full Text] [Related]
42. 'Basket studies' will hold intricate data for cancer drug approvals. Willyard C Nat Med; 2013 Jun; 19(6):655. PubMed ID: 23744135 [No Abstract] [Full Text] [Related]
43. Host pharmacogenetics in the treatment of HIV and cancer. Winston A; Hatzimichael E; Marvin V; Stebbing J; Bower M Curr Drug Saf; 2006 Jan; 1(1):107-16. PubMed ID: 18690920 [TBL] [Abstract][Full Text] [Related]
44. Pharmacology and pharmacogenetics of chemotherapeutic agents. Dawood S; Leyland-Jones B Cancer Invest; 2009 Jun; 27(5):482-8. PubMed ID: 19479485 [TBL] [Abstract][Full Text] [Related]
45. Raf: a strategic target for therapeutic development against cancer. Beeram M; Patnaik A; Rowinsky EK J Clin Oncol; 2005 Sep; 23(27):6771-90. PubMed ID: 16170185 [TBL] [Abstract][Full Text] [Related]
46. Pharmacogenetic and Pharmacokinetic Dose Individualization of the Taxane Chemotherapeutic Drugs Paclitaxel and Docetaxel. Andriguetti NB; Raymundo S; Antunes MV; Perassolo MS; Verza SG; Suyenaga ES; Linden R Curr Med Chem; 2017; 24(33):3559-3582. PubMed ID: 28641556 [TBL] [Abstract][Full Text] [Related]
47. Pharmacogenetics of neoplastic diseases: new trends. Di Paolo A; Danesi R; Del Tacca M Pharmacol Res; 2004 Apr; 49(4):331-42. PubMed ID: 15202512 [TBL] [Abstract][Full Text] [Related]
48. Methods: for studying pharmacogenetic profiles of combination chemotherapeutic drugs. Di Paolo A; Polillo M; Lastella M; Bocci G; Del Re M; Danesi R Expert Opin Drug Metab Toxicol; 2015; 11(8):1253-67. PubMed ID: 26037261 [TBL] [Abstract][Full Text] [Related]
55. Pharmacogenetics in cancer therapy - 8 years of experience at the Institute for Oncology and Radiology of Serbia. Cavic M; Krivokuca A; Boljevic I; Brotto K; Jovanovic K; Tanic M; Filipovic L; Zec M; Malisic E; Jankovic R; Radulovic S J BUON; 2016; 21(5):1287-1295. PubMed ID: 27837635 [TBL] [Abstract][Full Text] [Related]
56. Expression genomics and drug development: towards predictive pharmacology. Liu ET Brief Funct Genomic Proteomic; 2005 Feb; 3(4):303-21. PubMed ID: 15814022 [TBL] [Abstract][Full Text] [Related]
57. Pharmacological Profile and Pharmacogenomics of Anti-Cancer Drugs Used for Targeted Therapy. Di Francia R; De Monaco A; Saggese M; Iaccarino G; Crisci S; Frigeri F; De Filippi R; Berretta M; Pinto A Curr Cancer Drug Targets; 2018; 18(5):499-511. PubMed ID: 28183252 [TBL] [Abstract][Full Text] [Related]
58. Market watch: emerging companion diagnostics for cancer drugs. August J Nat Rev Drug Discov; 2010 May; 9(5):351. PubMed ID: 20431558 [No Abstract] [Full Text] [Related]
59. Interpreting disparate responses to cancer therapy: the role of human population genetics. Maitland ML; DiRienzo A; Ratain MJ J Clin Oncol; 2006 May; 24(14):2151-7. PubMed ID: 16682733 [TBL] [Abstract][Full Text] [Related]